Moderna, Inc. (MRNA)

Moderna's investigational flu vaccine denied FDA review, shares drop

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) shares fell almost 6% after the drugmaker announced that the US Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) has issued a Refusal-to-File (RTF) letter for the company's biologics license application for its investigational seasonal influenza vaccine, mRNA-1010. According to the company, the FDA cited the choice of a licensed standard-dose influenza vaccine as the comparator in Moderna's Phase 3 trial as the reason for the refusal.

MRNA Down Nearly 10% as FDA Refuses to Review Influenza Vaccine BLA

Moderna shares sink 10% after FDA issues Refusal-to-File letter for its mRNA-1010 flu vaccine, citing trial design concerns despite no safety flags.

Moderna's work developing seasonal vaccines is ‘risky' under current FDA, analyst says

The biotech company said the FDA won't review its flu vaccine, in the latest hit to mRNA development.

Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?

Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.

Moderna (MRNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here is What to Know Beyond Why Moderna, Inc. (MRNA) is a Trending Stock

Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.

MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs today announced the launch of the Defiance Daily Target 2X Long MRNA ETF (MRNX) , expanding its lineup of single-stock leveraged ETFs designed for active traders seeking amplified exposure to innovative companies at the forefront of biotechnology and life sciences. MRNX is designed for traders seeking magnified, short-term bullish exposure to Moderna, Inc. (NASDAQ: MRNA), a biotechnology company known for its messenger RNA (mRNA)–based medicines and vaccine development platform.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know

Moderna (MRNA) concluded the recent trading session at $42.55, signifying a -3.45% move from its prior day's close.

Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today?

Moderna, Inc. and Novavax, Inc. have transitioned from pandemic-era highs to focusing on cost reduction, pipeline development, and a path to breakeven by 2028. NVAX leverages partnerships with Sanofi and Pfizer, targeting ~$500m annual revenues by 2030, with a forward P/S of ~3x and P/E of ~7.5x. MRNA's growth depends on COVID/flu combo vaccine, intismeran cancer program, and RSV vaccine, but faces higher risk due to elevated spending and lack of major partners.

Moderna CMO Jacqueline Miller to step down

Moderna's Chief Medical Officer Jacqueline Miller, who led the development of the company's mRNA-based COVID-19 vaccine Spikevax, will step down effective March 2, the vaccine maker said on Friday.

MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data

Moderna rises after five-year phase IIb data show the combo of intismeran autogene plus Keytruda cuts recurrence or death risk by 49% in high-risk melanoma.

Moderna is curbing investment in vaccine trials due to US backlash

Moderna CEO Stephane Bancel said the company doesn't plan to invest in new late-stage vaccine trials because of growing opposition to immunizations from US officials https://bloom.bg/3LNHufg

Moderna curbing investments in vaccine trials due to US backlash, CEO tells Bloomberg TV

Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to immunizations from U.S. officials, CEO Stephane Bancel said in an interview with Bloomberg TV on Thursday.

MRNA Stock: Why 16% Pop May Signal More Upside

What's Happening With Moderna Stock?

Moderna stock surged 16% yesterday after receiving promising clinical trial results for its experimental skin cancer vaccine. The firm is working on mRNA-1893/V940, a personalized cancer vaccine developed in collaboration with Merck, which yielded encouraging outcomes in minimizing melanoma recurrence when paired with Keytruda immunotherapy.

Moderna Pops 17%—Is There Life in MRNA, Down 90% from COVID High?

In a blast from the past, COVID-19 vaccine developer Moderna NASDAQ: MRNA just made headlines in 2026. Shares jumped up more than 17% on Jan. 13, Moderna's largest single-day up-move in over three years.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week?

MRNA shares rise after upbeat 2025 sales, stronger cash outlook and detailed 2026 guidance, alongside multiple pipeline milestones.

Moderna expects 2025 revenue of $1.9B, above guidance

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) said it expects 2025 revenue of approximately $1.9 billion, about $100 million above the midpoint of its previously communicated guidance of $1.6 to $2 billion. The company also raised its 2025 GAAP operating expense outlook by $200 million to a range of $5 to $5.2 billion and projects a year-end cash balance of approximately $8.1 billion, including a $0.6 billion drawdown from a recently announced $1.5 billion term loan facility.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Moderna Stock Fights Back Against Four‑Year Curse With 20% Blastoff And A Golden Cross

Within the first week of 2026, the S&P 500 leaderboard has already delivered a surprise. Moderna Inc (NASDAQ: MRNA) has quietly muscled its way into the top year-to-date performers, up more than 20% in just three trading days, and the technicals suggest the move may not be a fluke.

MRNA Stock Jumps on Global Submissions Seeking Nod for Flu Vaccine

Moderna jumps after filings seeking approval for its mRNA-1010 flu vaccine across major markets, with plans to launch the shot for older adults next year.

Moderna (MRNA) Stock Dips While Market Gains: Key Facts

The latest trading day saw Moderna (MRNA) settling at $32.29, representing a -7.48% change from its previous close.

MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab

Moderna secures up to $54.3 million from CEPI to fund a pivotal phase III study of its mRNA-based H5 pandemic flu vaccine candidate, mRNA-1018.

CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike

CHMP backs EU approval of Moderna's next-generation mNexspike COVID-19 vaccine, with a final European Commission decision expected shortly.

Moderna 2026 Covid and RSV growth not enough to boost stock, Jefferies says

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) has been awarded a ‘Hold' rating and $30 price target, implying limited upside, from Jefferies analysts in their initial coverage of the drugmaker. Moderna shares are down almost 28% in the year to date, trading just shy of $30 on Friday morning.

Moderna (MRNA) Recently Broke Out Above the 50-Day Moving Average

Moderna (MRNA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MRNA broke through the 50-day moving average, which suggests a short-term bullish trend.

Moderna (MRNA) Just Reclaimed the 200-Day Moving Average

From a technical perspective, Moderna (MRNA) is looking like an interesting pick, as it just reached a key level of support. MRNA recently overtook the 200-day moving average, and this suggests a long-term bullish trend.

Moderna (MRNA) Recently Broke Out Above the 20-Day Moving Average

Moderna (MRNA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, MRNA crossed above the 20-day moving average, suggesting a short-term bullish trend.